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Molecular chaperones monitor the proper folding of misfolded proteins and function as the first line of defense against mutant
protein aggregation in neurodegenerative diseases. The eukaryotic chaperonin TRiC is a potent suppressor of mutant protein
aggregation and toxicity in early stages of disease progression. Elucidation of TRiC functional regulation will enable us to better
understand the pathological mechanisms of neurodegeneration. We have previously shown that vaccinia-related kinase 2
(VRK2) downregulates TRiC protein levels through the ubiquitin-proteasome system by recruiting the E3 ligase COP1. How-
ever, although VRK2 activity was necessary in TRiC downregulation, the phosphorylated substrate was not determined. Here, we
report that USP25 is a novel TRiC interacting protein that is also phosphorylated by VRK2. USP25 catalyzed deubiquitination of
the TRiC protein and stabilized the chaperonin, thereby reducing accumulation of misfolded polyglutamine protein aggregates.
Notably, USP25 deubiquitinating activity was suppressed when VRK2 phosphorylated the Thr680, Thr727, and Ser745 residues.
Impaired USP25 deubiquitinating activity after VRK2-mediated phosphorylation may be a critical pathway in TRiC protein
destabilization.
Protein misfolding and aggregation causes several neurodegen-erative diseases. For example, aggregation of huntingtin (Htt)
protein leads to Huntington’s disease (HD). An expanded muta-
tion in a polyglutamine (polyQ) stretch (35 residues) at the
N-terminal of Htt produces mutant Htt (mHtt), which is easily
misfolded and amyloidogenic (1, 2). The number of glutamines in
the polyQ stretch positively correlates with symptom severity and
inversely correlates with the age of symptom onset (2). mHtt ag-
gregates sequester many transcriptional factors via aberrant pro-
tein interactions, and these sequestrations cause transcriptional
inhibition of genes such as brain-derived neurotrophic factor
(BDNF) and its cognate receptors, which are responsible for neu-
ronal survival and function (3–6). Moreover, mHtt aggregates im-
pair axonal transport and mitochondrial function, resulting in
striatal neuron cell death in the basal ganglia and cortex (7, 8). As
a result, HD patients exhibit obvious symptoms, including chorea,
psychiatric impairments, and cognitive deficits (1).
To cope with aggregate-mediated cytotoxicity, cells possess de-
fense machinery called molecular chaperones. Within cells, mo-
lecular chaperones regulate proper folding of misfolded proteins
into their correct conformations (9). Studies have revealed that
molecular chaperones alleviate neurodegeneration by modulating
aberrant protein interactions in the early stages of aggregation (10,
11). Therefore, it is necessary to understand the upstream path-
ways controlling molecular chaperone protein levels in order to
develop novel therapeutics. Because expression of chaperones
such as heat shock proteins (HSPs) is affected by heat shock factor
protein 1 (HSF1), various pharmacological agents have been de-
veloped to enhance HSF1 transcriptional activity by inhibiting
HSP90, which negatively regulates HSF1 activation (12, 13). How-
ever, expression of eukaryotic chaperonin TCP-1 ring complex
(TRiC), a potent suppressor of polyQ aggregation and toxicity, is
not regulated by HSF1 transcriptional activity. TRiC protein levels
are elevated by inhibition of the degradation pathway. Although
the novel vaccinia-related kinase 2 (VRK2) is involved in TRiC
turnover, the molecular mechanisms of TRiC protein degradation
remain unclear (14). It is, therefore, necessary to examine VRK2
function in TRiC protein degradation to provide better therapeu-
tic insights into TRiC-assisted alleviation of polyQ toxicity.
VRK2 is highly expressed in proliferating cells such as cancer
cells and negatively regulates mitogen-activated protein kinase
signaling by interacting with the scaffold proteins JNK-interacting
protein (JIP1) and kinase suppressor of ras 1 (KSR1) (15, 16).
VRK2 also promotes cancer cell invasion by elevating the tran-
scriptional activity of nuclear factor of activated T cells 1 (NFAT1)
by VRK2-mediated phosphorylation (17). In addition, VRK2 pre-
vents apoptosis by interacting with Bcl-xL, an antiapoptotic Bcl-2
homology (BH) domain protein, which is involved in BAX gene
expression and regulates mitochondrial function (18). Recently,
VRK2 function in the brain has been noted in psychiatric disor-
ders, including schizophrenia and epilepsy. Using genome-wide
associated analyses, researchers observed a single-nucleotide poly-
morphism, rs2312147, located upstream of VRK2 among patients
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with schizophrenia that conferred an increased risk of schizophre-
nia (19, 20).
We have addressed here whether VRK2 regulates TRiC protein
degradation, which affects polyQ aggregation. In our previous
study, VRK2 increased TRiC protein degradation by promoting
ubiquitination, and TRiC ubiquitination was dependent on VRK2
enzymatic activity (14). However, the molecular mechanism of
VRK2 and its putative substrates have remained largely unexplored.
Here, we identified ubiquitin-specific protease 25 (USP25) as a
VRK2 substrate that acts on TRiC deubiquitination. These find-
ings suggest that VRK2 is important for the eukaryotic chaperonin
TRiC protein degradation pathway and is involved in polyQ pro-
tein aggregation.
MATERIALS AND METHODS
Plasmids. VRK2 (accession number NM_027260) and TRiC expression
constructs were generated by PCR amplification of mouse full-length
VRK2 and TRiC subunits (CCT1 to CCT8) from a day 16 mouse embryo
cDNA library (Clontech, Mountain View, CA). The USP25 construct was
purchased from DNASU plasmid repository (clone ID HSCD00442918).
For mammalian expression constructs, VRK2, USP25, and TRiC subunits
were subcloned into pFlag-CMV2 (Sigma, St. Louis, MO), pDsRed1-N1,
and pDsRed1-C1 (BD Biosciences, San Jose, CA) vectors, as well as vector
pcDNA3.1 containing hemagglutinin (HA) sequences. For expression in
Escherichia coli, VRK2 and USP25 were subcloned into pProEX, pGEX-
4T-1, and pGEX-4T-3 (Amersham, Piscataway, NJ) vectors. USP25 mu-
tants were generated by site-directed mutagenesis. Htt-exon1-GFP-
pcDNA3.1 (length of polyQ tract  25 or 103) was a gift from Judith
Frydman (Stanford University, Stanford, CA). The HA-ubiquitin con-
struct was a gift from Joo-Yeon Yoo (Postech, Pohang, South Korea).
Biochemical methods. Protein extraction and preparation, glutathi-
one S-transferase (GST) pulldown, and immunoblotting were performed
as previously described (14).
In vitro kinase assays.Kinase assays utilized 1g of recombinant GST
(or His)-VRK2 and 1 g of recombinant GST-USP25 (full length, frag-
ments, or mutants) as the substrates. The reaction was performed at 30°C
in 20-l reaction mixtures containing kinase buffer (20 mM Tris-HCl
[pH 7.5], 5 mM MgCl2, 0.5 mM dithiothreitol, 150 mM KCl, and
[-32P]ATP). After 30 min, the reactions were resolved by SDS-PAGE and
visualized with autoradiography.
In vitro deubiquitination assays. Ubiquitinated CCTs were immu-
noprecipitated from cells transfected with HA-ubiquitin and treated with
MG132 using the anti-CCT antibody. Ubiquitinated CCTs and 1 g of
GST-USP25 or USP25 mutants (C178S or phosphomimic) were added in
a buffer containing 20 mM Tris (pH 7.5) and 0.5 mM dithiothreitol.
Incubation was performed at 37°C for 2 h, followed by 16°C overnight.
Fluorescence microscopy. Mammalian cells were grown on cover-
slips until they reached 50 to 60% confluence. Transfected cells were
maintained for 24 h, fixed with 4% paraformaldehyde for 15 min, and if
necessary, immunostained with appropriate primary and fluorescence-
conjugated secondary antibodies. Coverslips were mounted onto slides
using Fluoromount (Sigma). An Axioplan2 fluorescence imaging micro-
scope (Carl Zeiss, Jena, Germany) equipped with an ApoTome (Carl
Zeiss) was used to obtain fluorescence or differential interference contrast
images.
Cell culture, transfection, and immunoprecipitation. HEK293A,
HEK293T, and SH-SY5Y cells were grown in Dulbecco modified Eagle
medium supplemented with 10% fetal bovine serum and 100 U/ml
each of penicillin G and streptomycin. Transient transfections were
performed using Metafectene reagent (Biontex, Munich, Germany) or
Microporator (Invitrogen) as described in the manufacturer’s proto-
cols. For immunoprecipitation, cell extracts were incubated with ro-
tation with the indicated antibody at 4°C for 1 h and precipitated with
protein G-agarose beads (Roche, Mannheim, Germany) overnight.
Immunoprecipitates were washed five times with lysis buffer and sub-
jected to immunoblotting.
siRNA sequences. The small interfering RNA (siRNA) duplex pool
targeting human USP25 was obtained from Dharmacon (Lafayette, CO).
The siRNA sequence for the nonspecific control oligonucleotide was CC
UACGCCACCAAUUUCGUdTdT.
Antibodies. Commercially available antibodies were as follows: anti-
Flag epitope (M2) from Sigma; anti-HA epitope from Roche (Mann-
heim, Germany); anti-glyceraldehyde-3-phosphate dehydrogenase (anti-
GAPDH) from Calbiochem (San Diego, CA); anti-CCT1, anti-CCT2,
anti-CCT4, and anti-USP25 from Abcam (Cambridge, United Kingdom);
anti-VRK2, anti-green fluorescent protein (anti-GFP), antiubiquitin, an-
ti-His epitope, and anti-GST from Santa Cruz Biotechnology (Santa Cruz,
CA); anti-Hsp70 from Enzo Life Sciences (Farmingdale, NY); and anti-
actin from MP Biomedicals (Santa Ana, CA). All fluorescence-conjugated
secondary antibodies were purchased from Invitrogen.
Quantitative real-time reverse transcription-PCR. Total RNA was
isolated with TRI Reagent (Molecular Research Center). Isolated RNA
was reverse transcribed by using an ImProm-II reverse transcription
system (Promega) according to the manufacturer’s instructions. For
detection and quantification, the StepOnePlus real-time PCR system
(Applied Biosystems) was used. The sequences of the forward and
reverse primers were as follows: human hsp70 (5=-AGCCAAGAAGGC
AAAAGTGA-3= and 5=-CCACTGCGTTCTTAGCATCA-3=) and hu-
man gapdh (5=-GCCATCAATGACCCCTTCATT-3= and 5=-GCTCCT
GGAAGATGGTGATGG-3=).
Statistical analyses.All quantitative data are presented as means the
standard deviations (SD) or standard errors of the mean (SEM). Statistical
analyses were performed using one-way analyses of variance and post hoc
Tukey’s multiple-comparison tests and GraphPad software. Differences
were considered significant when the P value was0.05.
RESULTS
USP25 interacts with the chaperonin TRiC. Because increased
CCT4 ubiquitination is dependent on VRK2 enzymatic activity,
we sought to identify substrate proteins that function in the ubiq-
uitination of chaperonin (14). To delineate the molecular mech-
anisms of TRiC protein degradation, we attempted to identify a
novel binding partner of TRiC. After lysates of TRiC subunit-
expressing cells (CCT2, CCT4, and CCT8) were incubated with
the anti-HA antibody, proteins associating with HA-CCT2, HA-
CCT4, and HA-CCT8 were immunoprecipitated. Using matrix-
assisted laser desorption ionization–time of flight (MALDI-TOF)
analyses, cytoplasmic USP25 was determined to be a novel inter-
acting protein of the chaperonin subunits (Fig. 1A). To further
confirm the binding between CCT4 and USP25, we performed
immunoprecipitation assays with cells transfected with Flag-
USP25 and HA-CCT4. The coprecipitated CCT4 was hardly de-
tectable without proteasomal inhibitor MG132, but it was evident
in the presence of MG132, which results in the accumulation of
ubiquitinated proteins (Fig. 1B and C). In order to determine
which subunit of TRiC binds to USP25, immunoprecipitation ex-
periments were performed with TRiC subunits (CCT1 to CCT8)
in HEK293A cells. When HA-TRiC subunits CCT1, CCT3, CCT4,
CCT5, and CCT7 were coexpressed with Flag-USP25, they were
efficiently coimmunoprecipitated using anti-HA antibody (Fig.
1D and E). Notably, the interaction between USP25 and TRiC was
detected in the presence of MG132 (Fig. 1C), suggesting that
USP25 recognizes ubiquitinated TRiC rather than its native form.
USP25 has one ubiquitin-associated domain (UBA) and two
ubiquitin-interacting motifs (UIMs) (21), which are important
for recognition of ubiquitinated substrates. To map the USP25
binding domains for TRiC, we performed pulldown assays to ob-
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serve the interactions between CCT4 and various USP25 frag-
ments. We found that the second UIM deletion fragment (147 to
1055) lost binding capacity to CCT4, whereas the UBA domain
deletion fragment (91 to 1055) or both UBA domain and the first
UIM deletion fragment (121 to 1055) still had interaction with
CCT4 (Fig. 1F; also see Fig. 4F). These data suggest that USP25
interacts with TRiC subunits and that the second UIM is critical
for recognition of ubiquitinated CCT4.
USP25 deubiquitinates CCT4. USP25 is a deubiquitinating
enzyme (DUB) that catalyzes removal of ubiquitin from its sub-
strates. Ubiquitination of target proteins is important for sub-
strate recognition of DUBs (22). To this end, we investigated
whether USP25 could deubiquitinate CCT4. Ubiquitinated CCT4
was incubated with USP25 or enzymatically inactive USP25
(C178S) (21) proteins that were purified from Escherichia coli.
Although the purified proteins did not change polyubiquitination
of CCT2, which had no interaction with USP25, CCT4 polyubiq-
uitination was decreased when incubated with USP25 but not
with enzymatically inactive USP25 (C178S) (Fig. 2A; see Fig. S1 in
the supplemental material). Conversely, USP25 knockdown en-
hanced CCT4 polyubiquitination and reduced CCT4 protein lev-
els (Fig. 2B). These data suggest that catalytically active USP25
deubiquitinates CCT4 and stabilizes it. To further confirm the role
of the deubiquitinating enzyme USP25 against other TRiC sub-
units, we examined polyubiquitination of CCT1, CCT2, and
CCT4 in cells transfected with Flag-USP25. Based on the interac-
tion of USP25 with TRiC subunits (Fig. 1D and E), we found that
USP25 catalyzed the deubiquitination of CCT1 and CCT4 but not
CCT2 (Fig. 2C). Taken together, these results show that USP25
functions as a DUB for ubiquitinated TRiC, which is dependent
on ubiquitinated substrate recognition.
Physiological role ofUSP25 in polyQ aggregation.To further
examine the physiological role of USP25 on TRiC protein stabil-
ity, we evaluated polyQ aggregation using the polyQ-expanded Htt
fragment fused to GFP when USP25 protein levels were modulated.
Growing evidences reveal that functional TRiC inhibits polyQ aggre-
gation at early stages and alleviates soluble or insoluble toxic species-
mediated harmful effects (10, 14). Notably, overexpression of either a
specific TRiC subunit or recombinant CCT1 significantly suppresses
polyQ aggregation and neuronal cell death (23, 24). We coexpressed
Flag-USP25 or enzymatically inactive USP25 (C178S) with patho-
genic HttQ103-GFP in HEK293A cells. Because USP25 stabilizes
FIG 1 USP25 interacts with TRiC via the second UIM domain. (A) Lysates from HEK293T cells transfected with HA-CCT2, HA-CCT4, and HA-CCT8 were
divided into cytoplasmic and nuclear fractions and then incubated with anti-HA antibody. Precipitated proteins were visualized by silver staining and analyzed
with MALDI-TOF. Cytoplasmic USP25 was determined to be a novel interacting protein of TRiC by immunoprecipitation with CCT2, CCT4, and CCT8. (B and
C) Immunoprecipitation assays using HEK293T cells cotransfected with Flag-USP25 and HA-CCT4 vectors in the absence (B) or presence (C) of MG132 (10
M). HA-CCT4 was coimmunoprecipitated with anti-Flag antibody. (D) TRiC subunits 1, 3, 4, 5, and 7 were efficiently coimmunoprecipitated by USP25. (E)
Calculated amounts of bound USP25 with TRiC subunits. Error bars represent the means the SEM (n 3). (F) Serial deletions of domains that are responsible
for substrate binding which indicated the second UIM of USP25 is important for TRiC binding.
Kim et al.
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TRiC protein levels by detaching polyubiquitin chains from the
TRiC proteins, the formation of HttQ103-GFP aggregates was de-
creased in Flag-USP25-overexpressing cells (Fig. 3A and B). In
addition, the number of double-labeled cells containing large foci
of aggregated HttQ103-GFP in wild-type USP25-expressing cells
reduced ca. 40% compared to control (Fig. 3C and D). Moreover,
mutant USP25 (C178S) did not significantly affect polyQ aggre-
gation and CCT4 protein levels, suggesting that the deubiquitinat-
ing enzyme activity of USP25 is important for polyQ aggregation.
Conversely, HttQ103-GFP aggregate formation was increased in
SH-SY5Y cells transfected with siRNA against USP25, which re-
duced CCT4 protein levels (Fig. 3E and F). Consistent with the
immunoblot observations, USP25 knockdown increased the
number of cells containing large foci of aggregated HttQ103-GFP,
as detected by fluorescence imaging (Fig. 3G and H).
USP25 is phosphorylated by VRK2. Since VRK2 reduced
CCT4 protein levels by promoting ubiquitination in a kinase-de-
pendent manner and triggered the accumulation of polyQ aggre-
gates (14), we tested whether VRK2 could regulate USP25 deubiq-
uitinating activity toward ubiquitinated CCT4. In order to
confirm the interaction between VRK2 and USP25, we performed
pulldown assays with cells cotransfected with Flag-VRK2 and HA-
USP25. VRK2 weakly interacted with USP25 (Fig. 4A). Fluores-
cence imaging analyses previously showed that VRK2 is localized
in the endoplasmic reticulum membrane due to its C-terminal
transmembrane domain (25). Unlike VRK2, USP25 diffuses
throughout the cytoplasm (Fig. 4B). Although the interaction is
weak, VRK2 could phosphorylate USP25 (Fig. 4C). To clarify the
effect of VRK2-mediated USP25 phosphorylation, we constructed
three fragments of USP25 to find the specific phosphorylation
sites (Fig. 4F). After purifying His-VRK2 protein and three frag-
ments of USP25, we performed in vitro kinase assays. VRK2 phos-
phorylated fragment 3 (F3, amino acids [aa] 655 to 1055) that
containing the regulatory domain, whereas fragment 1 (F1, aa 1 to
146), which includes one UBA and two UIM domains, and frag-
ment 2 (F2, aa 147 to 654), which contains a ubiquitin-specific
peptidase domain, were not phosphorylated by VRK2 (see Fig.
S2A in the supplemental material). We further divided USP25 F3
into three fragments, F3-1 (aa 655 to 780), F3-2 (aa 781 to 910),
and F3-3 (aa 911 to 1055), and purified them from transformed E.
coli cultures. By in vitro kinase assays, we found that only USP25
F3-1 is phosphorylated by VRK2 (see Fig. S2B in the supplemental
material). To determine the VRK2-specific phosphorylation
sites of USP25, we generated USP25 mutants by replacing the
putative Ser and Thr phosphorylation sites to Ala. Substitution
mutants of Thr680, Thr727, and Ser745 to Ala showed reduced
VRK2-mediated USP25 phosphorylation (Fig. 4D). When we
performed in vitro kinase assays with VRK2 and the triple site
mutant (Thr680, Thr727, and Ser745), phospho-USP25 was com-
pletely abrogated (Fig. 4E).
USP25 has decreased deubiquitinating activity when it is
phosphorylated by VRK2. In a previous report regarding post-
translational regulation of USP25 activity, sumoylation of USP25
within its two UIMs impaired its capability to bind ubiquitinated
substrates (26). To further verify the effect of VRK2-mediated
USP25 phosphorylation, we examined its ability to catalyze ubiq-
uitinated CCT4 in cells treated with MG132 after USP25 was pre-
incubated with or without VRK2 in the kinase reaction. Interest-
FIG 2 USP25 catalyzes deubiquitination of TRiC. (A) In vitro deubiquitination assays with purified GST-USP25 or mutant USP25 (CS, C178S) and ubiquiti-
nated CCT4 from cells treated with MG132. Polyubiquitinated CCT4 was immunoblotted with anti-HA antibody to detect HA-ubiquitin. (B) Immunoprecipi-
tation assays with anti-CCT4 and SH-SY5Y cells transfected with HA-ubiquitin and siRNA against USP25. Cells were treated with MG132 (10 M) before
harvest, followed by incubation of the cell lysates with the anti-CCT4 antibody. Immunoprecipitated CCT4 was subjected to Western blot analyses with the
anti-HA antibody (upper panel). Endogenous CCT4 protein in cells transfected with siUSP25 was investigated by Western blotting analyses with the anti-CCT4
antibody (bottom panel). (C) Polyubiquitination levels of CCT1, CCT2, and CCT4 in cells expressing USP25 were analyzed by Western blotting with anti-CCT1,
-CCT2, and -CCT4 antibodies.
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ingly, we found that phosphorylated USP25 showed markedly
impaired deubiquitination of CCT4 (Fig. 5A). Furthermore, the
phosphomimic mutant (Thr680, Thr727, and Ser745 to Glu) was
also unable to catalyze deubiquitination of CCT4 (Fig. 5B and C).
However, there was no difference in substrate binding, protein
stability and subcellular localization between phosphomimic mu-
tant USP25 and wild-type USP25 (see Fig. S3A to C in the supple-
mental material). Because the USP25 phosphomimic mutant has de-
fect on deubiquitinating activity, it did not affect polyQ aggregation
and CCT4 protein levels (see Fig. S3C to E in the supplemental ma-
terial). Collectively, our results suggest that VRK2 suppresses the deu-
biquitinating activity of USP25 via posttranslational modification
and, as a result, destabilizes TRiC.
DISCUSSION
HD is a late-onset and devastating neurodegenerative disorder.
Although there have been many attempts to find a cure for the
disease, no therapeutic medications have been developed. Al-
though there are many pathological features, HD pathogenesis is
ascribed to aggregation of mHtt, which leads to striatal neuron cell
death in the basal ganglia. Therefore, targeted therapies for HD
could inhibit mHtt aggregation or prevent cellular damage result-
ing from mHtt cytotoxicity. Approaches to decrease mHtt protein
levels include allele-specific silencing expression of the mutant
HTT gene (27), as well as the activation of autophagy (28) and the
ubiquitin-proteasome system (29). In addition, inhibition of
mHtt aggregation by elevating molecular chaperones, as well as
FIG 3 USP25 enhances the chaperone activity of TRiC in reducing polyQ-expanded Htt aggregation in mammalian cells. (A) HttQ103-GFP with Flag-USP25
or the inactive mutant USP25 (C178S) were coexpressed in HEK293A cells, followed by Western blotting to detect polyQ aggregates. (B) Calculated ratio of
insoluble to soluble mHtt levels. Error bars represent the means  the SD (n  4). *, P  0.05; ***, P  0.001. (C) Fluorescence microscopic images of
HttQ103-GFP and Flag-USP25 or USP25 (C178S) expressed in HEK293A cells. (D) Percentages of double-labeled cells containing large foci with USP25.
Medians, confidence intervals, and the SD are represented (n 3). *, P 0.05. Total counted cell numbers are shown at the bottom. (E) HttQ103-GFP, with or
without siRNA against USP25, was cotransfected into SH-SY5Y neuroblastoma cells, and HttQ103 aggregates were investigated by immunoblotting. (F)
Calculated ratio of insoluble to soluble mHtt levels. Error bars represent the means  the SD (n  3). **, P  0.01. (G) Fluorescence microscopy of
HttQ103-GFP-expressing SH-SY5Y cells treated with siUSP25 or siCont.USP25 knockdown increased number of cells containing HttQ103-GFP aggregates. (H)
The percentage of aggregate-positive cells from panel G was calculated. Median, confidence intervals, and the SD are represented (n 4). **, P 0.01. Total
counted cell numbers are shown at the bottom. Scale bars represent 60 m in panels C and G.
Kim et al.
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antiaggregation drugs, is beneficial for the early stages of HD
pathogenesis (13, 30). Trehalose was reported to reduce the symp-
toms of HD (31), and we previously found that guanidine-conju-
gated trehalose derivatives were delivered to the brain across the
blood-brain barrier and exhibited improved therapeutic effects in
HD model mice (30). Furthermore, there are approaches to alle-
viate the harmful effects of mHtt, including transcriptional dys-
regulation, mitochondrial impairment and excitotoxicity, or
apoptotic cell death (32).
Although mHtt aggregate formation in the cortex and striatum
is considered the hallmark of HD, a number of studies have re-
vealed that the soluble oligomer is more toxic than insoluble ag-
gregates (33, 34). Because molecular chaperones function in the
proper folding of misfolded mutant proteins before formation of
aberrant protein interactions, elevating the molecular chaperone
protein levels would be a rational approach to reduce soluble
mHtt oligomers. Although other molecular chaperones, such as
heat shock proteins, could be easily induced by activating HSF1,
expression of the eukaryotic chaperonin TRiC hetero-oligomeric
complex is not regulated by HSF1 transcriptional activity. How-
ever, a recent study has revealed that HSF1 is regulated by TRiC
(35). Because TRiC directly interacts with HSF1 and represses its
transcriptional activity, disturbance of the interaction results
HSF1 target gene expression, such as hsp70. Therefore, we exam-
ined whether VRK2-mediated USP25 phosphorylation, which re-
sults in TRiC destabilization, has effect on HSF1 activity. Interest-
ingly, we found that hsp70 mRNA level was not changed by
phosphomimic mutant USP25 expressing cells, but the protein
level showed difference between wild-type USP25 and phospho-
mimic mutant USP25 (see Fig. S4A to C in the supplemental ma-
terial). These data suggest that TRiC destabilization by VRK2-
mediated USP25 phosphorylation does not affect HSF1 tran-
scriptional activity but decreases the Hsp70 protein level. Since
Hsp70 has been known to be polyubiquitinated and degraded by
proteasome (36), its stability may be regulated by USP25 directly.
Moreover, -actin, a TRiC-client protein, was slightly decreased
FIG 4 VRK2 binds to and phosphorylates USP25. (A) Immunoprecipitation assays using HEK293T cells cotransfected with Flag-VRK2 and HA-USP25 vectors.
(B) Colocalization of VRK2 and USP25. HEK293A cells were cotransfected with EGFP-VRK2 and Flag-USP25 and stained for Flag (red) and nuclei (Hoechst;
blue). Scale bar, 20 m. (C) In vitro kinase assays with His-VRK2 and GST-USP25 derived from E. coli. (D) Site-directed mutagenesis of candidate phosphor-
ylation sites in USP25 fragment 3-1, followed by in vitro kinase assays with His-VRK2. (E) In vitro kinase assays with His-VRK2 and the triple site mutant (Thr680,
Thr727, and Ser745 to Ala). (F) Diagram of USP25 and fragments. UBA, ubiquitin-associated domain; SIM, SUMO-interacting motif; UIM, ubiquitin-interacting
motif.
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when phosphomimic mutant USP25 was overexpressed com-
pared to wild-type USP25 (see Fig. S4D in the supplemental ma-
terial). To summarize, elevating active chaperonin TRiC levels by
inhibiting VRK2-mediated USP25 phosphorylation has beneficial
effects on proper protein folding and stability. Elucidation of how
TRiC protein is degraded will allow us to understand pathological
disease mechanisms as well as suggest drug targets for the treat-
ment of neurodegenerative diseases. We previously demonstrated
that VRK2 plays an important role in TRiC protein turnover by
promoting ubiquitin-proteasomal degradation (14). However,
the exact function of VRK2 in TRiC protein degradation remained
unclear.
Here, we extensively investigated whether VRK2 controls TRiC
ubiquitination by inhibiting USP25 catalytic activity via post-
translational modification (Fig. 6). Notably, we demonstrated that
USP25 is a novel deubiquitinating enzyme for TRiC. USP25 cata-
lyzes the deubiquitination of CCT1 and CCT4, which are promi-
nent subunits that suppress mHtt aggregation. DUBs are isopep-
tidases regulating the ubiquitination state of target proteins (22).
The catalytic activity of DUBs is tightly controlled by posttransla-
tional modifications such as acetylation, sumoylation, ubiquitina-
tion, and phosphorylation. These modifications have been re-
ported to affect DUBs in several ways, including localization,
adaptor protein binding, protein stability, and catalytic activity
(37). Posttranslational modifications of USP25 also regulate its
DUB functions, which impair binding of the ubiquitin chain by
sumoylation (26) and protein degradation by SYK-mediated
phosphorylation (38). Furthermore, we have shown that VRK2-
mediated phosphorylation of USP25 causes impairment of DUB
activity for CCT4 deubiquitination.
Because the levels of TRiC represent the chaperone capacity for
ameliorating toxicity resulting from misfolded proteins, VRK2-
mediated downregulation of TRiC expression may be critical for
the onset and progression of misfolded protein-associated neuro-
degenerative diseases. VRK2 expression is reported to be main-
tained at low levels in the brain (39). However, in neurological
disorders, VRK2 mRNA levels were upregulated in the brains
from patients with schizophrenia compared to normal controls
(20). Moreover, polyQ aggregation was increased in active VRK2-
expressing SH-SY5Y neuroblastoma cells (14). Further studies
that determine whether VRK2 levels and activity are elevated in
brains from HD patients will provide promising evidence to help
us understand VRK2 function in HD pathogenesis. Although the
physiological role of VRK2 in the brain remains to be investigated,
FIG 5 USP25 is impaired by VRK2-mediated phosphorylation. (A) In vitro deubiquitination assays for purified GST-USP25 with or without kinase reaction of
VRK2 were performed with ubiquitinated CCT4 from MG132-treated cells. Before incubation with ubiquitinated CCT4, USP25 was subjected to VRK2-
mediated phosphorylation. Polyubiquitinated CCT4 was immunoblotted with anti-HA antibody to detect HA-ubiquitin. (B) Polyubiquitination levels of CCT4
in cells expressing USP25 and the phosphomimic mutant USP25 (PM, triple mutation to Glu) were analyzed by Western blotting with anti-HA antibody. (C) In
vitro deubiquitination assays with purified GST-USP25 or PM and ubiquitinated CCT4 from cells treated with MG132. Polyubiquitinated CCT4 was investigated
by immunoblotting.
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our results raise the possibility that inhibition of VRK2 enzymatic
activity would be a potential therapeutic target for the treatment
of many neurodegenerative diseases.
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